More MS news articles for September 2002

IL-6 in autoimmune disease and chronic inflammatory proliferative disease

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12220549&dopt=Abstract

Cytokine Growth Factor Rev 2002 Aug;13(4-5):357
Ishihara K, Hirano T.
Department of Molecular Oncology (C7), Graduate School of Medicine, Osaka University, 2-2 Yamada-oka Suita, 565-0871, Osaka, Japan

Interleukin 6 (IL-6), which was originally identified as a B-cell differentiation factor, is now known to be a multifunctional cytokine that regulates the immune response, hematopoiesis, the acute phase response, and inflammation.

Deregulation of IL-6 production is implicated in the pathology of several disease processes.

The expression of constitutively high levels of IL-6 in transgenic mice results in fatal plasmacytosis, which has been implicated in human multiple myeloma.

Increased IL-6 levels are also observed in several diseases, including rheumatoid arthritis (RA), systemic-onset juvenile chronic arthritis (JCA), osteoporosis, and psoriasis.

IL-6 is critically involved in experimentally induced autoimmune disease, such as antigen-induced arthritis (AIA), and experimental allergic encephalomyelitis.

All these clinical data and animal models suggest that IL-6 plays critical roles in the pathogenesis of autoimmune diseases.

Here we review the evidence for the involvement of IL-6 in the pathophysiology of autoimmune diseases and chronic inflammatory proliferative diseases (CIPD) and discuss the possible molecular mechanisms of its involvement.